Investor Relations

Regencell Bioscience Holdings Limited (“Regencell”) is an early-stage bioscience company that commenced operations in Hong Kong in 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system, such as COVID-19.
Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets.
Regencell also entered into a joint venture with Honor Epic Enterprises Limited and is expected to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.